Flare Therapeutics
Stub active Updated Jul 1, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Flare Therapeutics is a Cambridge, MA-based oncology biotech developing small-molecule degraders and modulators targeting transcription factors, a class historically considered undruggable 1. The company’s lead program, FX-111, is a degrader of the androgen receptor (AR) targeting prostate cancer; the company received IND clearance and plans to initiate Phase 1A clinical development in Q3 2026 1. Flare was founded by Abbie Celniker, Partner at Third Rock Ventures 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-30 | Series C | $85M | Third Rock Ventures, Nextech Invest | Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, Eventide Asset Management 1 |
The insider-led Series C coincided with the appointment of Anna Protopapas as Chief Executive Officer 1.
What Investors Say
“We believe FlareTx’s ARON-targeting approach is highly differentiated and has the potential to address important limitations of current prostate cancer therapies.” — Kanishka Pothula, Nextech Invest, Flare Therapeutics Series C announcement, June 30, 2026 1
“Our continued support of FlareTx into this next phase of growth is a testament to the differentiated transcription factor platform.” — Abbie Celniker, Founder, Flare Therapeutics Series C announcement, June 30, 2026 1
What Founders Say
“This is an exciting time for Flare Therapeutics and for patients with prostate cancer who desperately need new options.” — Anna Protopapas, CEO, Flare Therapeutics Series C announcement, June 30, 2026 1
Sources
-
Flare Therapeutics press release, “Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer,” June 30, 2026. Accessed July 2026. https://www.flaretx.com/flare-therapeutics-secures-85m-in-insider-led-series-c-financing-and-appoints-anna-protopapas-as-chief-executive-officer/↩↩↩↩↩↩↩↩